Table 2.

Features of PLZF–RARα and NPM–RARα leukemic mice

Mouse No.	Onset, days	PB M/L	BM M/L	BM pathology	Spleen pathology	Liver pathology
31*	39	2.1	ND	CML-L	ND	ND
33*	38	0.9	64	CML-L	EDI	FI
34*	85	1.6	75	CML-L	EDI	FI
74*	43	1.2	ND	CML-L	ND	FI
153*	31	3.6	90	CML-L	EDI	FI
23*	330	2.3	15	CML-L	EDI	FI
6†	368	6.7	15	APL	EDI	FI
16†	418	3.4	12.5	CML-L	EDI	FI
20†	414	1.8	ND	APL	EDI	‡
7†	441	1.4	26.3	MDS	SE‡	‡

ND, not determined; PB, peripheral blood; M/L, myeloid/lymphoid ratio; CML-L, CML-like picture, with significantly increased promyelocytes (≈20%) in BM; EDI, enlarged, damaged structure, and myeloid cell infiltration; FI, focal infiltration; SE, slightly enlarged; MDS, myelodysplasia syndrome. 

^*PLZF–RARα leukemic mice. 

^†NPM–RARα mice. 

^‡No obvious infiltration.